Market Movers (8-K)
See all →NASDAQ
Rapport Therapeutics announced positive Phase 2 results for RAP-219 in bipolar mania, with Phase 3 trials planned, and reported a Q3 2026 net loss of $40.2 million.
Capital raise
NASDAQ
Rapport Therapeutics successfully closed offerings of common stock, pre-funded warrants, and convertible senior notes, raising approximately $372 million to advance its clinical pipeline and for general corporate purposes.
Capital raise
NASDAQ
Rapport Therapeutics reports positive topline results from its Phase 2 trial of RAP-219 for bipolar mania, meeting primary and secondary endpoints with a well-tolerated safety profile.
Better than expected
NASDAQ
Rapport Therapeutics announced second quarter 2026 financial results, highlighting the initiation of its Phase 3 RAP-219 program for focal onset seizures and continued pipeline advancement.
NASDAQ
Rapport Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.
NASDAQ
Rapport Therapeutics reported Q1 2026 financials, highlighting progress in its RAP-219 epilepsy program, a new collaboration, and an extended cash runway.
Quarterly Earnings (10-Q)
See all →NASDAQ
Rapport Therapeutics, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, detailing progress in its neurological disorder drug development, including positive Phase 2 results for RAP-219 and a significant capital raise.
Worse than expected
Capital raise
NASDAQ
Rapport Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in R&D and a significant collaboration agreement.
Worse than expected
Capital raise
NASDAQ
Rapport Therapeutics announces Q1 2026 results, highlighting $20 million collaboration revenue and progress in clinical trials for RAP-219.
Worse than expected
Capital raise
NASDAQ
Rapport Therapeutics, a clinical-stage biotechnology company, announced positive topline results from its Phase 2a trial of RAP-219 for drug-resistant focal onset seizures, alongside a significant capital raise and continued operating losses.
Better than expected
Capital raise
Delay expected
NASDAQ
Rapport Therapeutics reports increased Q2 losses and R&D expenses, with a key pain trial on FDA clinical hold, while advancing its lead epilepsy and bipolar programs.
Delay expected
Worse than expected
Capital raise
NASDAQ
Rapport Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and research and development programs.
Delay expected
Annual Reports (10-K)
NASDAQ
Rapport Therapeutics focuses on precision medicines for neurological and psychiatric disorders, advancing its lead candidate for epilepsy while addressing regulatory hurdles in other indications.
Delay expected
Insider Trading (Form 4)
See all →NASDAQ
Third Rock Ventures V, L.P. and 5 others reported changes in beneficial ownership of Rapport Therapeutics, Inc. common stock on October 30, 2026.
NASDAQ
James Healy, a Director of Rapport Therapeutics, Inc., purchased 969,480 shares of common stock on October 28, 2026 for $21.00 per share.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on October 21, 2026 for $29.16 per share.
NASDAQ
Ramiro Sanchez, a Director of Rapport Therapeutics, Inc., purchased 3,600 shares of common stock on October 23, 2026 for $27.35 per share.
NASDAQ
Paul M Silva, a Director of Rapport Therapeutics, Inc., purchased 3,680 shares of common stock on October 22, 2026 for $27.07 per share.
NASDAQ
Wendy B. Young, a Director of Rapport Therapeutics, Inc., purchased 3,789 shares of common stock on October 22, 2026 for $26.39 per share.
Proxy Statements (Def-14A)
NASDAQ
Rapport Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to elect directors and ratify auditor appointment.
NASDAQ
DEFA14A: Rapport Therapeutics Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Rapport Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, with proposals including the election of Class I Directors and ratification of PricewaterhouseCoopers LLP as the independent accounting firm.
NASDAQ
Rapport Therapeutics announces its 2025 annual stockholder meeting to be held virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.
New Public Companies (S-1)
NASDAQ
Rapport Therapeutics files an amendment to its S-1 registration statement, including amended bylaws and details regarding its upcoming IPO and Nasdaq listing.
Capital raise
NASDAQ
Rapport Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to fund the development of its small molecule medicines for central nervous system disorders.
Capital raise
Worse than expected
Schedule 13D - Activist Investments
NASDAQ
Sofinnova Venture Partners XI and related entities, including Dr. James I. Healy, reported a decrease in their beneficial ownership of Rapport Therapeutics, Inc. common stock to below 5% due to dilution from the Issuer's recent share sales.
Capital raise
Schedule 13G - Passive Investments
See all →NASDAQ
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 5.12% of Rapport Therapeutics, Inc. common stock.
NASDAQ
Cormorant Asset Management, LP, through its associated funds, has reported beneficial ownership of 2,657,521 shares, representing 5.56% of the outstanding common stock of Rapport Therapeutics, Inc.
NASDAQ
Capital International Investors has disclosed a beneficial ownership of 6.1% in Rapport Therapeutics, Inc., holding 2,921,958 shares.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 6.19% of Rapport Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
Cormorant Asset Management and Bihua Chen report a 6.35% beneficial ownership stake in Rapport Therapeutics, Inc. common stock.
NASDAQ
BlackRock, Inc. has reported a 5.03% beneficial ownership stake in Rapport Therapeutics Inc. common stock as of December 31, 2025.